IgG hypersensitivity reactions to natalizumab have been described previously, and IgG against natalizumab is present in up to 12% of patients receiving natalizumab. 5 Other immunologic events, such as serum sickness-like delayed hypersensitivity reactions, have also been reported.
To our knowledge, we are describing the first case of a probable IgE-mediated hypersensitivity reaction to natalizumab diagnosed by means of an in vitro and in vivo study.
Monoclonal antibody and fusion protein therapy is rapidly increasing. Because of the complex molecular structure of immunoglobulins, a variety of heterogeneous immunologic reactions is possible. Assessing reactions to these therapies is a growing challenge to allergists. Infants aged 12 months can mount adequate serotype-specific IgG responses to pneumococcal polysaccharide vaccine
To the Editor: Streptococcus pneumoniae is a major cause of bacterial pneumonia, meningitis, bacteremia, and otitis media leading to an estimated 1 million deaths per year worldwide in children younger than 5 years. The capsule of S pneumoniae is the major virulence factor by which pneumococci cause invasive disease. Immunity against S pneumoniae is mediated by phagocytosis of the organism in the presence of complement and serotype-specific antibody. Capsular polysaccharide antigens, classified as T-independent type II antigens, are considered to stimulate B-lymphocytes directly to produce antigen-specific opsonic antibody without inducing immunologic memory or affinity maturation. Polysaccharide antigens, with bound complement C3d, are recognized directly by the B lymphocyte through CD21, which associates with CD19 to enhance and prolong antigen signaling. 1 On the basis of a limited number of small studies, the ability to mount T-independent responses is considered to be absent in the neonate and poor in children younger than 2 years. [2] [3] [4] This may be a result of lower CD21 expression on neonatal and infant B cells and/or the immaturity of the splenic marginal zone. 5 Pneumovax (Merck and Co, NJ), the 23-valent pneumococcal polysaccharide vaccine (23vPPV), contains 25 mg polysaccharide from each of 23 serotypes representing 85% to 90% of the serotypes causing invasive pneumococcal disease in the United States. Current guidelines define an adequate response to 23vPPV immunization as a 4-fold increase on preimmunization titer and/or a postimmunization titer > _1.3 mg/mL to at least 50% of serotypes tested for children age 2 to 5 years and at least 75% of serotypes for older children and adults. 6 These guidelines are based on results from small study cohorts or studies examining a limited number of serotypes. [2] [3] [4] 6 Previous studies suggest that infants 6 to 12 months of age can respond to some antigens in 23vPPV; however, these studies measured responses to only a few serotypes in a small number of subjects and used less specific older generation assay methods. [4] [5] [6] The ontogeny of the immune response to T-independent type II antigens in early life has not been formally assessed in larger groups of children.
In this study, the immunogenicity of 23vPPV was evaluated in 56 healthy Fijian infants who received 23vPPV as their primary pneumococcal vaccination at 12 months of age. Serotype-specific IgG to the 23 serotypes in the vaccine was measured by a standardized ELISA using cell wall polysaccharide and serotype 22F double absorption. 7 The geometric mean concentration (GMC) and 95% CI of serotype-specific IgG before and 2 weeks after immunization are reported in Table I . At 2 weeks post23vPPV, a greater than 4-fold increase in IgG GMC was detected for 18 (78%) of 23 serotypes, with a 2-fold increase in IgG GMC for serotypes 6B, 19A, 19F, and 23F. There was a significant increase (P < .05) over baseline at 2 weeks post-23vPPV for all serotypes except 14, 19F, and 23F. This response was maintained at 5 months post-23vPPV for 13 (57%) of 23 serotypes (data not shown).
The percentage of infants achieving an adequate response (either a 4-fold increase over baseline titer or a posttiter > _1.3 mg/mL) to each serotype is shown in Fig 1. All infants responded with a posttiter > _1.3 mg/mL to serotypes 2 and 8. Ninety-eight percent of infants mounted an adequate response to 11 of 23 serotypes (Table II) . Thirty-two infants (54%) responded to at least 17 of 23 serotypes. Two infants (4%) responded to all 23 serotypes. All infants responded to at least 9 of 23 serotypes. Serotypes 6B, 14, and 23F were the least immunogenic in this age group, with 12 infants (21%) producing an adequate response to serotypes 6B and 14, whereas 16 infants (29%) produced an adequate response to serotype 23F. Previous studies have also reported the low immunogenicity of serotypes 6B and 23F. 3 The number and selection of serotypes to be tested are critical to the evaluation of an adequate immune response to 23vPPV. The hierarchy of responses to pneumococcal serotypes 2 weeks post23vPPV in this population confirms that the selection of serotypes for measurement of specific IgG by laboratories is critical. If serotype-specific immune responses in this cohort were evaluated for 12 of the more immunogenic serotypes (eg, 2, 3, 4, 5, 7F, 8, 9N, 9V, 11A, 18C, 22F, and 33F), an adequate response would be detected in all infants. Conversely, if immune responses to 11 of the least immunogenic serotypes were assessed (eg, 1, 6B, 10A, 12F, 14, 15B, 17F, 19A, 19F, 20F, and 23F), 38% or 21 infants would be considered to have an inadequate response. If it is impossible to test all serotypes in the vaccine, the decision on which serotypes to assay should be based on the patient population and the serotypes causing disease in that population.
In 1998, Shann 8 suggested that a controlled trial of 23vPPV for children younger than 2 years was warranted considering the morbidity and mortality caused by S pneumoniae in this age group, the increasing antibiotic resistance of many of the bacterial strains, and the cost and the limited availability of pneumococcal conjugate vaccines in developing countries. We have shown 23vPPV to be immunogenic in this age group, with all infants enrolled in the study capable of producing adequate serotype-specific IgG to at least 9 of the 23 serotypes at 12 months of age.
Nevertheless, there are several issues concerning the use of 23vPPV in children younger than 2 years that require further clarification. It will be important to monitor the kinetics of the immune response over time, because recent studies and our own data raise the possibility that early administration of full-dose 23vPPV may result in immune hyporesponsiveness to subsequent challenge with polysaccharide antigens. 9 Further investigations including disease incidence and nasopharyngeal carriage data are required to clarify this issue. 
Regulation and characterization of IL-17A expression in patients with chronic rhinosinusitis and its relationship with eosinophilic inflammation
To the Editor:
IL-17A is a proinflammatory cytokine synthesized by T H 17 cells. 1 Although several reports have demonstrated that IL-17A expression levels in sputum and lung tissue correlated with the severity of asthma symptoms, it remains unclear as to whether IL-17A is involved in the pathogenesis of severe chronic upper airway diseases, including chronic rhinosinusitis with nasal polyps (CRSwNPs). 2, 3 We investigated the local production and regulation of IL-17A in nasal polyps (NPs) by using a recently developed ex vivo system. 4 In addition, local expression of IL-17A was compared among various chronic rhinosinusitis (CRS) phenotypes, and the role of IL-17A in the pathogenesis of CRS was discussed. Details on the methods are available in the Methods section of this article's Online Repository at www.jacionline.org.
Staphylococcus aureus enterotoxin B (SEB) is involved in the pathogenesis of CRSwNPs. 5 SEB stimulation of dispersed nasal polyp cells (DNPCs) induced significant IL-17A synthesis (Fig 1, A) , suggesting that SEB exerts its pathogenic effects in patients with CRSwNPs through induction of IL-17A synthesis. Neutralization with IL-10 or IL-18 did not affect the SEB-induced IL-17A synthesis. In contrast, neutralization with IL-12/IL-23 p40 partially, albeit significantly, suppressed this synthesis. IFN-g neutralization significantly improved IL-17A synthesis (Fig 1, B) . These results suggest that production of IL-17A is positively and negatively regulated by p40 and IFN-g, respectively.
The COX pathway also plays important roles in the pathogenesis of CRSwNPs. 4 Treatment with diclofenac caused a significant decrease in IL-17A production (Fig 1, A) . Conversely, SEB-induced IL-17A production in diclofenac-treated DNPCs was enhanced by 21.6%, 45.8%, and 38.8% in the presence of prostaglandin (PG) E 2 administered at 10 28 , 10 27 , and 10 26 mol/L, respectively, when compared with control buffer treatment (P 5 .001). PGE 2 , 10 27 and 10 26 mol/L, significantly increased IL-17A production compared with 10 28 mol/L PGE 2 , indicating that the effect of PGE 2 was dose dependent, and the highest enhancement was achieved at 10 27 mol/L (Fig 1, C) . This result suggests that COX metabolism, especially PGE 2 , displays a proinflammatory role during SEB-induced IL-17A production. The inhibition by p40 neutralization was also seen in the presence of diclofenac (P 5 .028), suggesting the additive inhibitory activity by COX inhibition and p40 neutralization. Serotypes 3 and 14 can be considered 2 extremes of a spectrum with respect to age-and serotype-dependent antibody responses to pneumococcal polysaccharides. In the study of Balloch et al, 1 in young children the highest postvaccination antibody concentration was found for serotype 3 (13.74 mg/mL), whereas the lowest postvaccination antibody concentration (and a nonsignificant response) was found for serotype 14 (0.41 mg/mL). 3 The opposite has been found in the elderly. In a recent study in elderly persons (>58 years old) in which antibodies to 14 serotypes were measured, the highest postvaccination antibody concentration was found for serotype 14 (19.76 mg/mL), whereas the lowest postvaccination antibody concentration was found for serotype 3 (1.19 mg/mL).
3 Thus children aged 1 year are unable to mount specific antibodies to serotype 14, 1,2 whereas elderly persons mount particularly high antibody responses to serotype 14 after vaccination with a 23-valent pneumococcal vaccine. [3] [4] [5] For serotype 14, Sorensen et al 6 also noted a pattern of increase according to age, with a very low mean fold increase in children but a sharply higher mean fold increase in adolescents and adults. In addition, children at age 1 year mount high specific antibody responses to serotype 3, whereas elderly persons mount weak antibody responses to serotype 3.
3,4 For serotype 3, lower postvaccination antibody levels have also been found in adults than in children. 7 Moreover, we found that even very young children were able to mount antibodies to serotype 3. In two 6-monthold children the postvaccination (Pneumovax; Merck & Co, Whitehouse Station, NJ) antibody concentrations to serotype 3 were 1.97 mg/mL and 2.3 mg/mL, respectively. 
